Human FGF-21 gene and gene expression products
AssigneesKyoto University, Novartis Vaccines and Diagnostics, Inc.
InventorsNobuyuki Itoh, Michael Kavanaugh
Life of this patent
Estimating the term…
Abstract
This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.
Claims3
An epitope-bearing portion of the polypeptide of SEQ ID NO:4 which comprises amino acids RQRYLYTDDAQQTEAH (SEQ ID NO:7).
An epitope-bearing portion of the polypeptide of SEQ ID NO:4 which comprises amino acids HLPGNKSPHRDPAPR (SEQ ID NO:8).
A pharmaceutical composition comprising the polypeptide of comprising amino acids from 1 to 209 of SEQ ID NO:4, in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.